Sociedad Americana de Hirudoterapia

Leech Cecropin

Cecropin-homolog antimicrobial peptide identified in the leech salivary secretome.

Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Leech Cecropin compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaLeech Cecropin4 kDa
Molecular weight (kilodaltons) of Leech Cecropin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Cecropin-homolog antimicrobial peptide identified in the leech salivary secretome.
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Aeromonas infection

Clinical translation limit

Leech cecropin is documented mechanistically only; no human evidence. In vitro antimicrobial activity does NOT establish clinical efficacy and does NOT mitigate the documented risk of Aeromonas hydrophila co-infection from whole-leech application.

Molecular Profile

Category
Antimicrobial
Evidence tier
Preclinical
Molecular weight
4,000 Da
Source species
Hirudo medicinalis
Discovered
2017
Leech Cecropin molecular structure

Biological Targets

  • Gram-negative bacterial membranes

Key Citations

  1. Liu Z et al. (2019), Parasit Vectors

External Resources

    Related Antimicrobial Compounds

    Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.